Regarding immunological parameters, a significant increase in T-cell ICOS expression (costimulatory molecule, third member of the CD28/CTLA-4 family) following ipilimumab treatment was found in melanoma patients who experienced disease control [120]. This evidence concerns the gene ICOS and melanoma.